Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Autifony Therapeutics Limited
With
King's College London
Age
18–50
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male patients with a diagnosis of schizophrenia no more than 5 calendar years (before screening);
Positive and negative symptoms assessed by PANSS;
Medically and psychiatrically stable;
On a stable dose of antipsychotic drugs;
Able to give fully informed written consent and likely to comply with the requirements of the trial.
You may not be if
clinically relevant, as assessed by a physician, abnormal findings at the screening assessment;
sensitivity to excipients of the trial medication;
current use of contraindicated drugs;
participation in another clinical trial of unlicensed medicines within the previous 30 days;
loss of more than 400 mL blood, within the previous 3 months; history of drug or alcohol dependence in the last year;
significant acute or chronic illness;
significant medical history or concurrent medical condition that warrants exclusion;
objection by subject's physician
Clareo Health | Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.
